Background: Allergen-specific immunotherapy is the most effective method of treatment in allergy to wasp venom. However, its mechanism of action is still not fully understood. The aim of this study is to describe changes in microRNA (miRNA) expression in patients undergoing the buildup phase of venom immunotherapy. Methods: The study group comprised 7 adult patients with a history of severe systemic reactions after stinging by a wasp. In all patients, sensitization to wasp venom had been confirmed by skin tests and serum IgE. The buildup phase of wasp venom immunotherapy (VIT) was conducted according to an ultrarush protocol. In blood samples collected before and 24 h after completing the VIT buildup phase, 740 miRNAs were assessed. Results: Of the 740 miRNAs, 440 were detected in the study group, and in 5 expression was significantly changed after the buildup phase of VIT: miR-370, miR-539, miR-502-3p, miR-299, and miR-29c. Another 62 miRNAs changed 2-fold in some patients (nonsignificant), including increases in miR-143 (stimulating FOXp3 expression) and let-7d (reducing expression of IL-13, IL-6, and TLR4), and decreases in proinflammatory miR-301, miR-146b, miR-106, and miR-485. Conclusions: Several changes in miRNA expression have been found as a result of the buildup phase of wasp VIT, with lower expression of some miRNAs involved in allergic inflammation and higher expression of those possibly involved in tolerance induction. However, the role of the most significant changes is uncertain.

1.
Erzen R, Kosnik M, Silar M, Korosec P: Basophil response and the induction of tolerance in venom immunotherapy: a long-term sting challenge study. Allergy 2012;67:822-830.
2.
Roever A, Henz B, Worm M: Wasp venom rush immunotherapy induces transient downregulation of B cell surface molecule expression. Int Arch Allergy Immunol 2002;127:226-233.
3.
Mobs C, Muller J, Rudzio A, Pickert J, Blank S, Jakob T, Spillner E, Pfutzner W: Decline of Ves v5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy. Allergy 2015;70:715-719.
4.
Meier P, Muller U: Evaluation of IgG RAST FEIA for the assay of venom-specific IgG antibodies during venom immunotherapy. Int Arch Allergy Immunol 1998;117:46-51.
5.
Varga E, Francis J, Zach M, Klunker S, Aberer W, Durham S: Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009;39:1353-1357.
6.
Niedoszytko M, Bruinenberg M, de Monchy J, Wijmenga C, Platteel M, Jassem E, Oude Elberink J: Gene expression analysis in predicting the effectiveness of insect venom immunotherapy. J Allergy Clin Immunol 2010;125:1092-1097.
7.
Hou B, Murata M, Said A, Sakaida H, Masuda S, Takahashi T, Zhang Z, Takeuchi K: Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy. Allergy Rhinol 2015;6:33-38.
8.
Bartel D: MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233.
9.
Lu T, Rothenberg M: Diagnostic, functional and therapeutic roles of microRNA in allergic diseases. J Allergy Clin Immunol 2013:132:3-13.
10.
Liu T, Munitz A, Rothenberg M: MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol 2009;182:4994-5002.
11.
Lu T, Sherill J, Wen T, Plassard A, Besse J, Abonia J: MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticosteroids and assessment as disease biomarkers. J Allergy Clin Immunol 2012;129:1064-1075.
12.
Shaoqing Y, Ruxin Z, Guojun L, Zhiqiang Y, Hua H, Shudong Y: Microarray analysis of differentially expressed microRNAs in allergic rhinitis. Am J Rhinol Allergy 2011;25:e242-e246.
13.
Zhang X, Zhang Y, Li H, Hu C, Wang N, Cao P: Overexpression of miR-125b, a novel regulator of innate immunity, in eosinophilic chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med 2012;185:140-151.
14.
Liu F, Qin H, Xu B, Zhou H, Zhao D: Profiling of miRNAs in pediatric asthma: upregulation of miRNA-221 and miRNA-485-3p. Mol Med Rep 2012;6:1178-1182.
15.
Qin H, Xu B, Mei J, Li D, Liu J, Zhao D, Liu F: Inhibition of miRNA-221 suppresses the airway inflammation in asthma. Inflammation 2012;35:1595-1599.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.